Table 3.
Subgroup analysis of the objective response rate (ORR), overall survival rate at 12 months (OS-12 m) and grade 3–4 adverse effects (grade 3–4 AEs) of B + E in patients with advanced HCC
| ORR | OS-12 m | |||||||
|---|---|---|---|---|---|---|---|---|
| Group | N | ES (95% CI) | P Values | I2 (%) | N | ES (95% CI) | P Values | I2 (%) |
| Total | 342 | 0.126 (0.063,0.190) | – | 70.0% | 298 | 0.437 (0.329,0.546) | – | 72.6% |
| ECOG | ||||||||
| 0–1 | 176 | 0.117 (0.009,0.224) | 0.956 | 77.6% | 176 | 0.376(.121,0.631) | 0.701 | 85.1% |
| 0–2 | 166 | 0.140 (0.044,0.236) | 73.3% | 122 | 0.470 (0.351,0.589) | 63.9% | ||
| Pre-schedule | ||||||||
| Prior systematic therapy | 180 | 0.145 (0.044,0.247) | 0.128 | 77.3% | 136 | 0.443 (0.243, 0.644) | o.456 | 83.5% |
| No systematic therapy | 162 | 0.103 (0.015,0.191) | 67.9% | 162 | 0.408 (0.332, 0.483) | 0.0% | ||
| Line of treatment | ||||||||
| First line | 162 | 0.103 (0.015,0.191) | 0.089 | 68.9% | 162 | 0.408 (0.332, 0.483) | 0.048 | 0.0% |
| Second line | 180 | 0.145 (0.044,0.247) | 77.3% | 37 | 0.267(−0.007,0.542) | 83.5% | ||
| Region | ||||||||
| America | 237 | 0.161 (0.068,0.258) | 0.014 | 76.7% | 237 | 0.481 (0.369,0.592) | 0.517 | 65.2% |
| Not America | 105 | 0.071 (0.020,0.123) | 0.0% | 61 | 0.308(−0.036,0.652) | 87.2% | ||
| Liver functions | ||||||||
| Child-Pugh class A/B | 147 | 0.170 (0.019,0.321) | 0.224 | 84.2% | 147 | 0.524 (0.418,0.630) | < 0.001 | 40.5% |
| Child-Pugh class A | 195 | 0.098 (0.044,0.153) | 38.4% | 151 | 0.341 (0.179,0.503) | 74.4% | ||
Note: Liver functions: the subgroup of Child-Pugh class A and B refers patients enrolled with liver function of Child-Pugh class B excess 10%, otherwise the subgroup of Child-Pugh class A. ES Effect size, ORR objective response rate, OS overall survival, AEs adverse effects, B + E bevacizumab combined with erlotinib